Persist, Adapt, Resist: Has Cancer Met its Match in Small RNAs?

Technology Networks explores how small RNA therapeutics could counter cancer’s ability to persist, adapt, and resist. NUAgo Therapeutics CEO and Co-Founder, Robert Schickel, Ph.D., describes how targeting multiple survival genes at once sets the approach apart from traditional single-target therapies.